NASDAQ:APHA Aphria (APHA) Stock Price, News & Analysis → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Free APHA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.38▼$15.3850-Day Range$13.14▼$18.3752-Week Range$2.78▼$32.29VolumeN/AAverage Volume21.83 million shsMarket Capitalization$4.87 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aphria alerts: Email Address Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> About Aphria Stock (NASDAQ:APHA)Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Read More Ad Behind the MarketsTiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>> APHA Stock News HeadlinesSeptember 27, 2023 | benzinga.comSheep Ate 600lbs Of Cannabis While Sheltering From A Storm: Here's What They Did NextSeptember 25, 2023 | markets.businessinsider.comEwe Won't Believe It: Greek Sheep's 'Highly' Unconventional Cannabis Greenhouse AdventureApril 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.June 8, 2023 | markets.businessinsider.comTilray CFO Engages Shareholders On Reddit, Addresses Concerns And Company's Growth StrategyJanuary 3, 2023 | nypost.comHow to bet on Horse Racing: Complete guide to Horse Betting OnlineOctober 14, 2022 | fool.comWhy Owens & Minor Shares Plummeted 32.4% This Week - The Motley FoolOctober 11, 2022 | prnewswire.comThe Continued Legalization of Cannabis Creates Need for Intoxication Detection Devices - PR NewswireOctober 10, 2022 | finance.yahoo.comIndustrial hemp Market Size-2022 Will Revenue to Cross readjusted size of US$ 3259.5 million by 2028 Top Companies report covers, (It was also one of the primary plants to be rolled into usable fibre 50,000 years ago.) - Yahoo FinanceApril 19, 2024 | Behind the Markets (Ad)Tiny Biotech Stock Wins $75 Billion PatentA little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.October 8, 2022 | seekingalpha.comTilray Brands Stock: Pot Pops Then Drops - Seeking AlphaOctober 7, 2022 | law360.comJPay Founder Says Insider Trading Case Falls Short - Law360October 4, 2022 | businesswire.comGlobal Medical Marijuana Market Trends/Analysis Report 2022: A $65.8 Billion Industry by 2030 - Rapid Adoption of Cannabis in Therapeutic Applications - ResearchAndMarkets.com - Business WireOctober 1, 2022 | prnewswire.comGlobal Cannabis Extract Market to Reach $15.5 Billion by 2030 at a CAGR of 20.6% - PR NewswireSeptember 28, 2022 | businesswire.comGlobal Legal Cannabis Market Size, Trends & Analysis Report 2022-2030: Regulatory Scenario, Consumption Pattern, Potential Trade Opportunities, Case Studies, End-users, Competitive Landscape - ResearchAndMarkets.com - Business WireSeptember 27, 2022 | globenewswire.comCannabis Beverages Market to Reach USD 19,063.58 Million by - GlobeNewswireSeptember 26, 2022 | finance.yahoo.comGlobal Legal Cannabis Market Analysis Report 2022: A $134.4 Billion Industry by 2030, Growing at a CAGR of Over 25% - Yahoo FinanceSeptember 17, 2022 | seekingalpha.comTLRY Tilray Brands, Inc.September 14, 2022 | globenewswire.comWith 27.5% CAGR, Global CBD-Infused Beverages Market Size - GlobeNewswireSeptember 13, 2022 | prnewswire.comYourWay Cannabis Brands Provides Corporate Update - PR NewswireSeptember 13, 2022 | businesswire.comMorganti & Co., Announces that Class Certification Scheduled in the pending shareholder litigation against Auxly Cannabis Group, Inc. - Business WireSeptember 11, 2022 | benzinga.comJoana ScopelSeptember 10, 2022 | benzinga.comTilray Brands (NASDAQ:TLRY) – A Shareholder Lawsuit Stemming From Aphria Could Expose Tilray—Trouble In C - BenzingaSeptember 7, 2022 | investors.comIs TLRY Stock A Buy As Germany Gets Closer To Cannabis Legalization? - Investor's Business DailySeptember 2, 2022 | seekingalpha.comTLRY stock gains after debt agreement with JV partner (NASDAQ:TLRY) - Seeking AlphaSeptember 1, 2022 | law360.comCanadian Pot Co. Investors Win Class Cert. In Acquisition Suit - Law360August 31, 2022 | globenewswire.comIndustrial Hemp Market Worth USD 3259.5 million by 2028 | Growth, Size, Shares, Revenue, Types, Applications, Key Players, Top Countries, Growing Factors, Key Dynamics - GlobeNewswireAugust 25, 2022 | finance.yahoo.comTilray Medical Launches New Products and ‘CannaPoints’ Program to Support Patients Across Canada - Yahoo FinanceSee More Headlines Receive APHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aphria and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/11/2021Today4/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolNASDAQ:APHA CUSIPN/A CIKN/A Webaphriainc.com Phone(844) 427-4742FaxN/AEmployees1,200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,210,000.00 Net Margins-36.10% Pretax MarginN/A Return on Equity-2.30% Return on Assets-1.66% Debt Debt-to-Equity Ratio0.25 Current Ratio2.36 Quick Ratio1.17 Sales & Book Value Annual Sales$405.96 million Price / Sales12.00 Cash Flow$0.09 per share Price / Cash Flow166.43 Book Value$4.80 per share Price / Book3.20Miscellaneous Outstanding Shares316,795,000Free FloatN/AMarket Cap$4.87 billion OptionableOptionable Beta2.67 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Irwin D. Simon (Age 62)CEO & Chairman Comp: $5.23MMr. Carl A. MertonChief Financial OfficerDr. Christelle Gedeon L.L.B.Ph.D., Chief Legal Officer & Corp. Sec.Mr. James R. MeiersChief Operating Officer of Aphria LeamingtonMs. Denise Menikheim Faltischek (Age 48)Chief Strategy Officer & MD of Aphria Germany Comp: $449.68kMr. John B. SadlerVP of Investor RelationsMr. Bernard YeungSr. VP of Sales & MarketingMr. Victor Neufeld (Age 67)Special Advisor Mr. Cole Cacciavillani (Age 66)Special Advisor Mr. Randy DaigneauSr. VP of Supply ChainMore ExecutivesKey CompetitorsHalozyme TherapeuticsNASDAQ:HALOKrystal BiotechNASDAQ:KRYSCRISPR TherapeuticsNASDAQ:CRSPBausch + LombNYSE:BLCOGlaukosNYSE:GKOSView All Competitors APHA Stock Analysis - Frequently Asked Questions How were Aphria's earnings last quarter? Aphria Inc. (NASDAQ:APHA) issued its earnings results on Sunday, April, 11th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.04) by $1.10. The firm earned $153.60 million during the quarter, compared to analyst estimates of $172.01 million. Aphria had a negative net margin of 36.10% and a negative trailing twelve-month return on equity of 2.30%. The business's quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.02 earnings per share. Read the conference call transcript. What other stocks do shareholders of Aphria own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include AbbVie (ABBV), Alibaba Group (BABA), Mastercard (MA), Block (SQ), Abbott Laboratories (ABT), Alteryx (AYX), Big Lots (BIG) and BlackRock (BLK). This page (NASDAQ:APHA) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersThe “Perfect Storm” for GoldGold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceSHOCKING Crypto Leak…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aphria Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.